Approved Indications of Levetiracetam
Levetiracetam is FDA-approved as adjunctive therapy for three specific seizure types: partial onset seizures in adults and children ≥4 years, myoclonic seizures in patients ≥12 years with juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures in patients ≥6 years with idiopathic generalized epilepsy 1.
FDA-Approved Indications
The official FDA-approved indications are clearly delineated by seizure type and patient age:
Partial Onset Seizures
- Adjunctive therapy for partial onset seizures in adults and children 4 years of age and older with epilepsy 1
- This is the broadest approved indication with the youngest age cutoff
Myoclonic Seizures
- Adjunctive therapy for myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy 1
- Note the more restricted age range compared to partial seizures
Primary Generalized Tonic-Clonic Seizures
- Adjunctive therapy for primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy 1
- Intermediate age cutoff between the other two indications
Key Regulatory Points
All three FDA-approved indications specify levetiracetam as "adjunctive therapy," meaning it is approved for use in combination with other antiepileptic drugs, not as monotherapy 1. This is a critical distinction for prescribing practices and insurance coverage.
The drug is available in both oral and intravenous formulations. The IV formulation is approved as an adjunctive treatment in patients 16 years or older when oral administration is temporarily not feasible 2.
Off-Label Use in Clinical Practice
While not FDA-approved, levetiracetam is widely used off-label for status epilepticus management. The 2024 ACEP guidelines and the ESETT trial demonstrate that levetiracetam shows comparable efficacy to fosphenytoin and valproate for benzodiazepine-refractory status epilepticus, though this remains an off-label indication 3. The ESETT trial found no significant difference in seizure cessation rates between levetiracetam (47%), fosphenytoin (45%), and valproate (46%) 3.
Similarly, levetiracetam is used off-label for seizure prophylaxis in brain tumor patients, though the 2021 SNO/EANO guidelines recommend against routine prophylactic use in patients who have never had a seizure 4. When antiepileptic therapy is needed in brain tumor patients, levetiracetam may be preferred over older agents due to its more favorable side effect profile 4.
Common Pitfalls
- Do not prescribe levetiracetam as monotherapy based on FDA labeling—it is approved only as adjunctive therapy
- Age restrictions matter: A 3-year-old cannot receive levetiracetam for partial seizures under FDA approval; a 10-year-old cannot receive it for myoclonic seizures
- Status epilepticus use is off-label: While evidence-based and guideline-supported, this indication is not FDA-approved
- Prophylactic use in seizure-naive patients is not indicated: This applies particularly to neurosurgical and brain tumor patients